KIT exon 11 mutation
|
Melanoma
|
KIT exon 11 mutation
|
Melanoma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
KIT exon 11 mutation
|
Melanoma
|
KIT exon 11 mutation
|
Melanoma
|
nilotinib Sensitive: A2 - Guideline
|
nilotinib Sensitive: A2 - Guideline
|
KIT exon 11 mutation
|
Gastric Cancer
|
KIT exon 11 mutation
|
Gastric Cancer
|
imatinib Sensitive: B - Late Trials
|
imatinib Sensitive: B - Late Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
ripretinib Sensitive: B - Late Trials
|
ripretinib Sensitive: B - Late Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
regorafenib Sensitive: B - Late Trials
|
regorafenib Sensitive: B - Late Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
imatinib Sensitive: C2 – Inclusion Criteria
|
imatinib Sensitive: C2 – Inclusion Criteria
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
ponatinib Sensitive: C2 – Inclusion Criteria
|
ponatinib Sensitive: C2 – Inclusion Criteria
|
KIT exon 11 mutation
|
Melanoma
|
KIT exon 11 mutation
|
Melanoma
|
imatinib Sensitive: C3 – Early Trials
|
imatinib Sensitive: C3 – Early Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
nilotinib Sensitive: C3 – Early Trials
|
nilotinib Sensitive: C3 – Early Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
KIT exon 11 mutation
|
GIST
|
KIT exon 11 mutation
|
GIST
|
avapritinib Resistant: C4 – Case Studies
|
avapritinib Resistant: C4 – Case Studies
|
KIT exon 11 mutation
|
Melanoma
|
KIT exon 11 mutation
|
Melanoma
|
dasatinib Resistant: C4 – Case Studies
|
dasatinib Resistant: C4 – Case Studies
|